1. Home
  2. CLLS vs RENE Comparison

CLLS vs RENE Comparison

Compare CLLS & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • RENE
  • Stock Information
  • Founded
  • CLLS 1999
  • RENE 2021
  • Country
  • CLLS France
  • RENE United States
  • Employees
  • CLLS N/A
  • RENE N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • RENE Blank Checks
  • Sector
  • CLLS Health Care
  • RENE Finance
  • Exchange
  • CLLS Nasdaq
  • RENE Nasdaq
  • Market Cap
  • CLLS 164.2M
  • RENE 151.4M
  • IPO Year
  • CLLS 2007
  • RENE 2022
  • Fundamental
  • Price
  • CLLS $1.69
  • RENE $11.66
  • Analyst Decision
  • CLLS Buy
  • RENE
  • Analyst Count
  • CLLS 3
  • RENE 0
  • Target Price
  • CLLS $7.00
  • RENE N/A
  • AVG Volume (30 Days)
  • CLLS 54.8K
  • RENE 3.0K
  • Earning Date
  • CLLS 11-04-2024
  • RENE 01-01-0001
  • Dividend Yield
  • CLLS N/A
  • RENE N/A
  • EPS Growth
  • CLLS N/A
  • RENE 42.92
  • EPS
  • CLLS N/A
  • RENE 0.43
  • Revenue
  • CLLS $36,042,000.00
  • RENE N/A
  • Revenue This Year
  • CLLS $271.02
  • RENE N/A
  • Revenue Next Year
  • CLLS $33.48
  • RENE N/A
  • P/E Ratio
  • CLLS N/A
  • RENE $26.90
  • Revenue Growth
  • CLLS 46.96
  • RENE N/A
  • 52 Week Low
  • CLLS $1.41
  • RENE $10.94
  • 52 Week High
  • CLLS $3.38
  • RENE $11.67
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 36.61
  • RENE 70.34
  • Support Level
  • CLLS $1.41
  • RENE $11.64
  • Resistance Level
  • CLLS $1.64
  • RENE $11.65
  • Average True Range (ATR)
  • CLLS 0.10
  • RENE 0.00
  • MACD
  • CLLS -0.03
  • RENE -0.00
  • Stochastic Oscillator
  • CLLS 19.09
  • RENE 100.00

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

About RENE Cartesian Growth Corporation II

Cartesian Growth Corp II is a blank check company.

Share on Social Networks: